Brouard M C, Prins C, Mach-Pascual S, Saurat J H
Department of Dermatology, University Hospital, Geneva, Switzerland.
Dermatology. 2001;203(1):57-9. doi: 10.1159/000051705.
The tyrosine kinase inhibitor STI571 is a novel promising class of anticancer drugs. We report a case of cutaneous adverse reactions to STI571 in a young woman with blast crisis of chronic myeloid leukemia. She had first typical acute generalized exanthematous pustulosis mimicking mercury rash and then urticarial eruption. We suggest that cell pathways mediated by some tyrosine kinases might be involved in the pathogenesis of these skin eruptions.
酪氨酸激酶抑制剂STI571是一类新型且有前景的抗癌药物。我们报告了1例患有慢性髓性白血病急变期的年轻女性发生STI571皮肤不良反应的病例。她先是出现了类似汞疹的典型急性泛发性脓疱病，随后出现了荨麻疹。我们认为某些酪氨酸激酶介导的细胞途径可能参与了这些皮疹的发病机制。
